It is worth noting that CCL2 can inhibit the normalization of induced blood vessels, while anti-CCL2 therapy can induce blood vessel normalization and improve tumor perfusion, thereby enhancing tumor-targeted drug delivery and anti-cancer nanotherapy (189). This evidence concerns the gene CCL2 and cancer.